FDA decision deadline on extending IMCIVREE to Bardet-Biedl syndrome (BBS) patients aged 2 to <6. PDUFA was extended from June 30 to August 12 after a CMC amendment. IMCIVREE is Rhythm’s only commercial product.
What’s at stake
IMCIVREE (setmelanotide) is a daily subcutaneous injection approved for treating severe, early-onset obesity caused by rare genetic defects in the melanocortin pathway — specifically POMC, PCSK1, or LEPR mutations, and Bardet-Biedl syndrome. The drug is a melanocortin-4 receptor (MC4R) agonist that bypasses the broken signaling proteins and directly activates the hypothalamic receptor that controls hunger and energy expenditure. Patients with these mutations experience extreme, treatment-resistant obesity from childhood because their brains cannot generate or respond to satiety signals; IMCIVREE is the only approved pharmacological option for these ultra-rare syndromes.
No primer in glossary yet.
This event was extracted from a primary disclosure. The full chain of citations is in the disclosure trail below.
- PDUFAregulatoryPrescription Drug User Fee Act
The FDA's self-imposed review deadline for an NDA/BLA. Standard reviews are ~10 months from filing; priority reviews are ~6 months.
- CMCregulatoryChemistry, Manufacturing, Controls
Section of an FDA submission covering how the drug is made, tested, and supplied. CMC issues are a common cause of CRLs.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| dapiglutide | VKTX | peptide | dual GLP-1 / GIP receptor agonist | CONFERENCE · May 26 | |
| RM-718 | RYTM | peptide | weekly MC4R agonist (next-gen) | READOUT · Oct 26 |
Disclosure trail
- Mar 18, 2026·1mo agopinned · highest confidenceHIGH conf8-KEXACT↗ 43dvs priortop claimAUG 122026
“On March 17, 2026, the Company received notice from the FDA extending the PDUFA action date by three months, to August 12, 2026, to provide time for review of additional CMC information submitted as a major amendment.”
contextItem 8.01 Other Events — 8-K filed March 18, 2026.
conf 97%via llm - Feb 8, 2026·2mo agoHIGH confPREXACTother claimJUN 302026
“The PDUFA action date for the supplemental NDA is set for June 30, 2026.”
conf 95%via llm